SCHEMBL2297974

SCHEMBL2297974

CCC(CC)n1c(O)nc2ncc(Cl)c(-c3cccc(OC(F)(F)F)c3)c21

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSA P10619 2/20 0.40
ADORA1 P30542 1/20 0.40
PIM1 P11309 5/20 0.38
ACLY P53396 1/20 0.38
DYRK1A Q13627 4/20 0.37
S1PR1 P21453 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KCNH2 Q12809 1/20 0.36
SCN10A Q9Y5Y9 1/20 0.36
CTSC P53634 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
ITGB1 P05556 1/20 0.36
ITGA4 P13612 1/20 0.36
ITGB7 P26010 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2296495 0.89 HRH3 (0.36) ADORA1ACLYCYP1A2CYP3A4CYP2C9
SCHEMBL2298966 0.88 JAK2 (0.40) ADORA1DYRK1A
SCHEMBL2295854 0.83 GRIN2B (0.36) ADORA1
SCHEMBL2297601 0.82 RECQL (0.34)
SCHEMBL3397374 0.81 NR1H2 (0.37) CTSAKCNH2
SCHEMBL3394660 0.81 CDK8 (0.41)
SCHEMBL2300115 0.80 TGFBR1 (0.35) DYRK1A
SCHEMBL3398945 0.80 CDK8 (0.34)
SCHEMBL2298152 0.79 DYRK1A (0.38) DYRK1A
SCHEMBL2299654 0.79 USP7 (0.40) CYP1A2CYP3A4KCNH2CTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS YANG ZHE (US) 2011-12-22 US claimed
US-20090253737-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INCORPORATED 2009-10-08 US claimed
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS YANG ZHE (US) 2011-12-22 US disclosed
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS YANG ZHE (US) 2011-12-22 US disclosed
US-7989469-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED (US) 2011-08-02 US disclosed
US-20090253737-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INCORPORATED 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253737-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS TNNC1, TNNI3, TNNT2 CTSA 2255/4885ADORA1 3223/4885PIM1 1559/4885
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS TNNC1, TNNI3, TNNT2 CTSA 2050/4885ADORA1 3055/4885PIM1 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.